Drug marketing largely left alone in House PDUFA hearings

02/7/2012

Although several entities have called for drug marketing restrictions or greater regulation of direct-to-consumer drug ads to be included in the Prescription Drug User Fee Act V (PDUFA V), there was just one mention of drug marketing during four-plus hours of testimony before the House Energy and Commerce Committee’s Subcommittee on Health at a Feb. 1 PDUFA V hearing. However, industry should not be lulled into thinking that these issues will not re-emerge as negotiations continue, according to Coalition for Healthcare Communication Executive Director John Kamp, who said “we’re watching carefully and remain prepared for a challenge.” Read more.

View Full Article in:

http://www.cohealthcom.org/2012/02/02/house-health-subcommittee-pdufa-v-hearing-...

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA